Showing 1841-1850 of 4063 results for "".
- Palatin Technologies Announces Reinitiation of Enrollment of Phase 2 Study With PL9643 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-reinitiation-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2477985/Palatin Technologies announced reinitiation of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After pausing patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic, Palatin has commenced patient recruitment in
- Aurinia Completes Patient Enrollment In Phase 2/3 Trial of Voclosporin for the Treatment of Dry Eyehttps://modernod.com/news/aurinia-completes-patient-enrollment-in-phase-2-3-trial-of-voclosporin-for-the-treatment-of-dry-eye/2477914/Aurinia Pharmaceuticals announced it has completed enrollment for the phase 2/3 AUDREY clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Voclosporin’s proven mechanism of action as a novel calcineurin inhibitor gives us
- Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Retinitis Pigmentosahttps://modernod.com/news/bionic-sight-llc-doses-first-patient-in-a-phase-1-2-clinical-trial-of-a-new-investigational-treatment-for-blindness-caused-by-retinitis-pigmentosa/2477902/Bionic Sight announced that it has dosed the first patient in the company’s phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with retinitis pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative dise
- US Hits 2 Million Coronavirus Cases As Many States See A Surge Of Patientshttps://modernod.com/news/us-hits-2-million-coronavirus-cases-as-many-states-see-a-surge-of-patients/2477891/The U.S. has reached another dire landmark in its fight against COVID-19, surpassing 2 million confirmed cases on Wednesday. New coronavirus infections are rising in at least 20 states, even as restrictions on daily life continue to ease across the country, according to an NPR
- ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through ARVOhttps://modernod.com/news/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-data-through-arvo/2479525/ProQR Therapeutics announced a virtual presentation of data from the company’s phase 1/2 trial of sepofarsen. The data will be shared via a video presentation through the Association for Research in Vision and Ophthalmology (ARVO). It is the first time this data, previously announced in a
- Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for DME Drug Candidatehttps://modernod.com/news/adverum-biotechnologies-announces-new-infinity-phase-2-trial-for-dme-drug-candidate/2477842/Adverum Biotechnologies announced the initiation of INFINITY, a phase 2, multicenter, randomized, double-masked, active comparator-controlled trial to assess a single intravitreal (IVT) injection of ADVM-022 in patients with diabetic macular edema (DME). The company also reported financial resul
- Novavax Initiates Phase 1/2 Trial of COVID-19 Vaccine Candidate NVX‑CoV2373https://modernod.com/news/novavax-initiates-phase-1-2-trial-of-covid-19-caccine-candidate-nvxe28091cov2373/2477822/Novavax on Monday announced that it has enrolled the first participants in a phase 1/2 trial of its coronavirus vaccine candidate NVX‑CoV2373, with preliminary results expected in July. The news follows the Coalition for Epidemic Preparedness Innovations (CEPI) recently awarding up to
- New Paper in Clinical and Experimental Optometry Summarizes SARS-CoV-2 Interaction With the Ocular Surfacehttps://modernod.com/news/new-paper-in-clinical-and-experimental-optometry-summarizes-sars-cov-2-interaction-with-the-ocular-surface/2477800/“The ocular surface, coronaviruses and COVID-19,” an extensive literature review now published in Clinical and Experimental Optometry, considers a number of questions regarding SARS-CoV-2 transmission and the ocular surface. In a complex and fast-moving subject area, the paper provides a
- Clyraguard Shows Complete Inactivation of SARS-CoV-2 Virus in Study at Galveston National Labhttps://modernod.com/news/clyraguard-shows-complete-inactivation-of-sars-cov-2-virus-in-study-at-galveston-national-lab/2477802/Clyra Medical Technologies announced that it has received test results showing that its proprietary copper iodine antimicrobial and antiviral product, Clyraguard, successfully inactivated the COVID-19 coronavirus (SARS-CoV-2 virus). Testing was conducted by the laboratory of Slobodan Paess
- Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-reports-topline-data-from-phase-2-trial-with-ocs-01-for-treating-inflammation-and-pain-following-cataract-surgery/2477782/Oculis SA reported positive results from its phase 2 SKYGGN study of OCS-01, a novel, high concentration, preservative free, topical SNP formulation of dexamethasone (ophthalmic suspension 1.5%) for the treatment of inflammation and pain following cataract surgery. OCS-01 has been develope